Recent Advances in Biomarkers and Regenerative Medicine for Diabetic Neuropathy

Fujita, Yoshikai; Murakami, Tatsufumi; Nakamura, Akihiro

doi:10.3390/ijms22052301

Cited by 23 publications

(18 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Blood biomarkers in diabetes have concentrated on the most common subtype of diabetic peripheral neuropathy, distal painful sensory neuropathy in patients with type 2 diabetes. Much of the work has concentrated on metabolic biomarkers and neurotrophic factors, given their role in nerve regeneration and repair 24 …”

Section: Diabetic Peripheral Neuropathymentioning

confidence: 99%

“…There have been a multitude of large case–control studies of patients with type 2 diabetes, with and without neuropathy, in which inflammatory and metabolic markers have been measured using cytokine and apocrine arrays 24 . These studies have consistently shown an increase in a number of inflammatory markers in type 2 diabetic patients with neuropathy compared to those without neuropathy; these include TLR 4, TNF alpha, TGF beta, CXCL10, MCP‐1, adhesion molecule E‐selectin and interleukins including IL‐6 IL‐1, IL12p70, IL‐13 and IL‐17A 25–29 .…”

Section: Diabetic Peripheral Neuropathymentioning

confidence: 99%

See 1 more Smart Citation

Blood biomarkers of peripheral neuropathy

Rossor

2022

Acta Neuro Scandinavica

View full text Add to dashboard Cite

Traditionally, neurophysiology is the primary diagnostic and prognostic biomarker in peripheral neuropathy clinical practice; however, it may lack responsiveness in the context of slowly progressive neuropathies and where there is significant axonal damage. The development of ultrasensitive platforms for measuring serum proteins at the lower limit of detection of traditional ELISA techniques has transformed the field of blood biomarkers of peripheral neuropathy. A variety of blood biomarkers have been identified from inflammatory cytokines and apokines in diabetic neuropathy through to neuron‐specific proteins such as neurofilament light chain, Schwann cell‐specific proteins such as TMPRSS5 and microRNAs in other acquired and hereditary neuropathies. In this article, we review blood biomarkers of disease activity for the common subtypes of peripheral neuropathy including inflammatory demyelinating neuropathies, vasculitic neuropathy, diabetic neuropathy, chemotherapy‐induced neuropathy and Charcot–Marie–Tooth disease and related disorders including TTR amyloidosis.

show abstract

Section: Diabetic Peripheral Neuropathymentioning

confidence: 99%

Section: Diabetic Peripheral Neuropathymentioning

confidence: 99%

Blood biomarkers of peripheral neuropathy

Rossor

2022

Acta Neuro Scandinavica

View full text Add to dashboard Cite

show abstract

“…In the developmental stage, it changes from alpha enolase form to gamma enolase in neural tissue. NSE is a potential hall-marker in diabetic complications including diabetic peripheral neuropathy and DR [60,61]. A clinical study revealed that an elevated level of NSE in serum was found in diabetes mellitus patients.…”

Section: Discussionmentioning

confidence: 99%

Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity

Subramanian

Thirunavukkarasu²,

Muthuraman³

2022

Processes

View full text Add to dashboard Cite

Retinopathy is one of the most common complications of diabetes mellitus. Diabetic retinopathy (DR) occurs due to microvascular damage in retinal tissues provoked by high blood sugar levels. The available drugs for DR are limited. Astaxanthin (AST) has anti-hypertensive, anti-obesity, and anti-diabetic properties. However, the therapeutic effect of AST on DR remains elusive. The present study is designed to investigate the effects of AST on DR via inhibition of neuron-specific enolase (NSE) activity. DR was induced by the administration of streptozotocin (STZ, 35 mg/kg: intraperitoneal; and 20 μL of STZ: intravitreal) in mice. AST (10 and 20 mg/kg) was administered orally (p.o.) for 21 days. The DR associated visual changes were assessed at different time intervals via optokinetic motor response (OMR) and penta-maze (PM) tests. Blood glucose level as well as retinal catalase, lactate dehydrogenase (LDH), & neuron-specific enolase (NSE) were estimated. The reference drug i.e., dexamethasone (DEX, 10 mg/kg; p.o.) was administered for 21 days. The administration of AST showed significant ameliorative potential in DR. Hence, AST can be used as a natural medicine for the management of DR due to its potential antioxidant, anti-diabetic, and NSE inhibitory properties.

show abstract

“…The primary symptoms of DPN are paresthesia and neuropathic pain in the lower limbs [ 5 , 6 ]. However, almost half of patients present asymptomatically in the early phases of DPN [ 7 ], which may result in delayed diagnosis and a high rehospitalization rate. Therefore, timely diagnosis and treatment are essential for preventing the progression and complications of DPN.…”

Section: Introductionmentioning

confidence: 99%

A Nomogram for Predicting the Possibility of Peripheral Neuropathy in Patients with Type 2 Diabetes Mellitus

Zhang

Chen

2022

Brain Sciences

View full text Add to dashboard Cite

Background and Purpose: Diabetic peripheral neuropathy (DPN) leads to ulceration, noninvasive amputation, and long-term disability. This study aimed to develop and validate a nomogram for forecasting the probability of DPN in type 2 diabetes mellitus patients. Methods: From February 2017 to May 2021, 778 patients with type 2 diabetes mellitus were included in this study. We confirmed the diagnosis of DPN according to the Toronto Expert Consensus. Patients were randomly divided into a training cohort (n = 519) and a validation cohort (n = 259). In the training cohort, univariate and multivariate logistic regression analyses were performed, and a simple nomogram was built using the stepwise method. The receiver operating characteristic (ROC), calibration curve, and decision curve analysis were computed in order to validate the discrimination and clinical value of the nomogram model. Results: About 65.7% and 72.2% of patients were diagnosed with DPN in the training and validation cohorts. We developed a novel nomogram to predict the probability of DPN based on the parameters of age, gender, duration of diabetes, body mass index, uric acid, hemoglobin A1c, and free triiodothyronine. The areas under the curves (AUCs) of the nomogram model were 0.763 in the training cohort and 0.755 in the validation cohort. The calibration plots revealed well-fitted accuracy between the predicted and actual probability in the training and validation cohorts. Decision curve analysis confirmed the clinical value of the nomogram. In subgroup analysis, the predictive ability of the nomogram model was strong. Conclusions: The nomogram of age, gender, duration of diabetes, body mass index, uric acid, hemoglobin A1c, and free triiodothyronine may assist clinicians with the early identification of DPN in patients with type 2 diabetes mellitus.

show abstract

Recent Advances in Biomarkers and Regenerative Medicine for Diabetic Neuropathy

Cited by 23 publications

References 81 publications

Blood biomarkers of peripheral neuropathy

Blood biomarkers of peripheral neuropathy

Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity

A Nomogram for Predicting the Possibility of Peripheral Neuropathy in Patients with Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About